| Identification | Back Directory | [Name]
DINOPROSTONE ETHANOLAMIDE | [CAS]
194935-38-1 | [Synonyms]
PGE2-EA
DINOPROSTONE ETHANOLAMIDE
PROSTAGLANDIN E2 ETHANOLAMIDE
Prostaglandin E2 Ethanolamide Exclusive
Prostaglandin E2 Ethanolamide MaxSpecStandard
Prostaglandin E2 Ethanolamide Lipid Maps MS Standard
N-(2-HYDROXYETHYL)-9-OXO-11ALPHA,15S-DIHYDROXY-PROSTA-5Z,13E-DIEN-1-AMIDE
(Z)-N-(2-hydroxyethyl)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enamide | [Molecular Formula]
C22H37NO5 | [MDL Number]
MFCD00797645 | [MOL File]
194935-38-1.mol | [Molecular Weight]
395.53 |
| Chemical Properties | Back Directory | [Boiling point ]
611.5±55.0 °C(Predicted) | [density ]
1.134±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [form ]
powder | [pka]
13.79±0.60(Predicted) |
| Hazard Information | Back Directory | [Description]
Prostaglandin E2 ethanolamide (PGE2-EA) is an analog of PGE2 with improved water solubility and stability. PGE2-EA is formed via COX-2 metabolism of arachidonoyl ethanolamide (AEA; ) and acts as an agonist at E prostanoid (EP) receptors 1-4 (Kis = 2.45, 0.46, 0.2, and 0.51 μM, respectively). It also inhibits indoleamine 2,3-dioxygenase-1 (IDO-1) in THP-1 cells and human monocytes (IC50s = 5.7 and 4.7 μM, respectively). PGE2-EA (10 μM) prevents morphological changes and F-actin rearrangement as well as reduces L-homocysteine-induced NLRP3 inflammasome formation and activation in podocytes. Ex vivo, PGE2-EA reduces luminal damage and lymphocyte infiltration in a human mucosal explant colitis model. | [Uses]
Prostaglandin E2 Ethanolamide-d4 is the isotope labelled analogue of Prostaglandin E2 Ethanolamide, an analogue of Prostaglandin E2 (P838610). Prostaglandin E2 is most common and most biologically potent of mammalian prostaglandins. | [Definition]
ChEBI: Prostaglandin E2 ethanolamide is a prostanoid. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|